Alembic shoots up on Pristiq generic approval and Ranbaxy tie
This article was originally published in Scrip
Shares of Alembic Pharmaceuticals rose 15% on Indian bourses after the company said that it had received US FDA approval for its NDA for desvenlafaxine base extended release tablets, a bioequivalent version of Pfizer's antidepressant Pristiq, and also firmed up a marketing alliance with Ranbaxy's US arm for the product.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.